
Sign up to save your podcasts
Or


Millions of customers have explored their genome with 23andMe. But when the company started in 2006, the idea of consumer DNA testing was heresy to the medical establishment. The FDA once even ordered 23andMe to stop selling its health testing product. The company persevered to make allies out of adversaries, and became the only FDA-approved product on the market. Learn how 23andMe defined the DNA testing category, and used its success to enter the massive new field of drug discovery.
Host: Roelof Botha, Sequoia Capital
Featuring: Anne Wojcicki, Richard Scheller
Transcript: https://www.sequoiacap.com/podcast/crucible-moments-23andMe/
By Sequoia Capital4.9
9090 ratings
Millions of customers have explored their genome with 23andMe. But when the company started in 2006, the idea of consumer DNA testing was heresy to the medical establishment. The FDA once even ordered 23andMe to stop selling its health testing product. The company persevered to make allies out of adversaries, and became the only FDA-approved product on the market. Learn how 23andMe defined the DNA testing category, and used its success to enter the massive new field of drug discovery.
Host: Roelof Botha, Sequoia Capital
Featuring: Anne Wojcicki, Richard Scheller
Transcript: https://www.sequoiacap.com/podcast/crucible-moments-23andMe/

1,290 Listeners

533 Listeners

2,168 Listeners

1,085 Listeners

2,105 Listeners

234 Listeners

5,478 Listeners

9,840 Listeners

500 Listeners

349 Listeners

260 Listeners

131 Listeners

497 Listeners

1,343 Listeners

40 Listeners